Updates to the NCCN's Guidelines for Waldenstrom's and Myeloma

Updates have been made to the National Comprehensive Cancer Network's (NCCN) Clinical Practice Guidelines in Oncology..

These updates were presented at the recent NCCN Annual Conference. The most important updates are outlined below for both Waldenstrom's Macroglobulinemia and Multiple Myeloma by Kenneth C. Anderson MD of Dana-Farber/Brigham and Women's Cancer Center by way of OncLive.

Waldenstrom's Macroglobulinemia

According to Dr. Anderson, these updates "incorporate major progress in our ability to identify a common mutation that helps determine proper treatment."

Imbruvica (ibrutinib) is now listed as a non-stem cell toxic salvage therapy option.

Specific bone marrow testing is now considered useful in the work-up for certain patients.

Therapeutic intent ought to be "based on palliation of symptoms and not necessarily levels of IgM, unless the patient is exhibiting evidence of symptomatic hyperviscosity."

Multiple Myeloma

Dr. Anderson writes that "none of the multiple myeloma updates will radically change clinical practice, but [there are] major changes to come."

The classical definition of smoldering myeloma using tests like plain x-rays is quickly growing outdated. New efforts are now modifying these criteria to reclassify patients from "asymptomatic" to "having active disease."

Also regarding smoldering myeloma, recent studies indicate that patients with "certain characteristics including IgG levels >3 g/dL, IgA>2 g/dL, urinary Bence Jones protein > 1 g/24 hours, or abnormal free light chain ratios, have an increased risk of progression to active myeloma."

Category 2B recommendations:

  • Bortezomib (Velcade) plus prednisone cited as an option for maintenance therapy
  • Bortezomib (Velcade) plus thalidomide (Thalomid) also cited as an option for maintenance therapy
  • A two-to-three year minimum length of remission before a second autologous stem cell transplant for salvage therapy

Source: OncLive

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap